Key Takeaways Innovative glaucoma therapies and global expansion efforts position the company for sustained revenue growth and reduced reliance on a single product. Emphasis on minimally invasive solutions and payer adoption strengthens long-term profitability and supports increased market share.Read more
Key Takeaways Accelerating adoption of innovative, minimally invasive eye therapies positions Glaukos for outsized revenue growth and expanding market share as treatment paradigms shift. Diversifying its pipeline across multiple ophthalmic conditions enables sustainable, long-term earnings growth beyond current core markets.Read more
Key Takeaways Reimbursement cuts, shifting treatment preferences, and intensifying competition threaten Glaukos' pricing power, market share, and long-term revenue growth. Heavy reliance on few products and high R&D spending expose Glaukos to earnings volatility and margin pressure if commercialization or adoption hurdles persist.Read more
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
